Metis TechBio Co., Ltd. Class H 7666
HKEX · Hong Kong SAR China · Process Industries
HKD 17.85+1.86 (+11.63%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
This is a news report by Hong Kong Ta Kung Wen Wei Media Group Limited:
METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary trispecific T-cell engager (TCE) program developed by METiS TechBio.
Short term share move puts Metis TechBio in focus Metis TechBio (SEHK:7666) has come onto investor radar after the stock fell about 10% in the latest session and is down around 24% over the past week. The company focuses on AI empowered nanomaterials for drug delivery. It reported revenue of HK$105.0 million and a net loss of CN¥391.836 million across its operations in Mainland China and the United States. See our latest analysis for Metis TechBio. At a latest share price of HK$18.0, Metis...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.